Posted by Michael Wonder on 03 Sep 2025
ICER publishes final evidence report on treatments for spinal muscular atrophy
2 September 2025 - Independent appraisal committee votes reflect uncertainty in net health benefit for apitegromab and for add-on treatments after gene therapy.
The ICER today released a final evidence report assessing the comparative effectiveness of apitegromab (Scholar Rock), as well as the disease-modifying therapies nusinersen sodium (Spinraza, Biogen), onasemnogene abeparvovec-xioi (Zolgensma, Novartis), and risdiplam (Evrysdi, Genentech) for spinal muscular atrophy.
